Specifically, SYK-mediated AKT activation inhibits GSK3 (glycogen synthase kinase 3), preventing the ubiquitination and proteasomal degradation of MCL-1, a key anti-apoptotic protein in chronic lymphocytic leukemia (CLL) and other malignancies. Here, SYK is linked to B-cell chronic lymphocytic leukemia.